Kornimate/medical-research-clean huggingface dataset:
identifying strategies to curtail weight regain after glp-1 receptor agonist treatment cessation

Conditions: Obesity

Summary: longitudinal studies show there is a steep increase in weight regain in the first 3-4 months after stopping glp-1 receptor agonist medications (glp-1s) and most patients regain most of their weight within a year. insurers now question the utility of glp-1s for weight loss as they are hesitant to cover these costs long-term (\~$833 per person per month). some patients would also prefer not to take these medications in perpetuity and are likely to struggle with lifelong adherence. these challenges present an opportunity to test alternative interventions, such as meal replacements and behavioral treatments, to support weight maintenance after successful weight loss with glp-1s. this regimen would allow patients to benefit from significant weight loss in the first year of taking glp-1s and use more cost effective and sustainable strategies for long-term maintenance.

in the proposed study the investigators will execute a pilot randomized controlled trial to identify whether medically tailored meals (mtm, group 1, n=20) and/or noom®, a mobile application (group 2, n=20) are associated with greater treatment adherence and satisfaction than usual care (group 3, n=20) after glp-1 receptor agonist cessation. the investigators will enroll adults 18 and older that have lost more than 10% of their bodyweight taking glp-1 receptor agonist and ceased treatment within the past 30-days. for four-months, group 1 will receive 40 mtm per month, group 2 will receive a noom® subscription, and group 3 will receive lifestyle counseling per standard of care.

Eligibility criteria:
inclusion criteria: * 18 years of age or older; * ability to read, write, and speak english; * ability to provide informed consent; * greater than 10% glp-1 receptor agonist induced weight loss * less than 30-days since glp-1 receptor agonist cessation; * willing to participate. exclusion criteria: * major psychiatric illness or substance misuse that could impair ability to participate; * presence of a medical condition or dietary restriction precluding eating study meals or weight loss (e.g., medical condition requiring liquid diet, pregnancy, eating disorder); * participation in a study or program involving medically tailored meals or noom® within the past 12-months.

Keywords: glucagon-like peptide-1 receptor agonists body weight maintenance
comparison of efficacy of ivabradine versus metoprolol

Conditions: Coronary Artery Disease

Summary: ivabradine may be better than metoprolol for controlling heart rate before coronary cta.


Eligibility criteria:
inclusion criteria: * elective patient on scheduled for 640 slices ct coronary at phramonkutklao hospital * resting heart rate \> 70 bpm * age \> 18 years and informed consent exclusion criteria: * heart rate \> 100 bpm * bp \<100/60 mmhg * recent congestive heart failure in 1 mo. * sa node, av node disease and af * on permanent pacemaker * crcl \ 3x unl * on hr reducing drug such as diltiazem, verapamil, digitalis * contraindication for ivabradine or metoprolol

Keywords: ct coronary coronary arterial disease ivabradine metoprolol
preventing chronicity of sub-acute low back pain by altering the neural emotional response to pain

Conditions: Preventive Medicine

Summary: aim of the study it could be stated that chronification of low back pain in some respects depends on the emotional reactions to the acute pain state. this approach enables advancing novel therapeutics for preventing pain chronification by altering the pain-related affective states. at present, no publication evaluating the efficacy of iet in altering brain responses related to sub-acute low back pain seems available. neither have we found any studies specifically addressing the efficacy of mindfulness training on the functional connection between pfc and nac. the aim of this study project is three-fold: 1. a systematic literature review of behavioural methods in the prevention of low back pain chronicity orenius t, silén e, nuortimo a, ristolainen l. psychological interventions in preventing chronicity of sub-acute back pain: a systematic review. scand j pain. 2022 jan 24;22(2):211-217. doi: 10.1515/sjpain-2021-0063. prospero: crd42019053580 2. a pilot study (n=7+7) to address the efficacy and feasibility of iet in preventing chronicity of sub-acute pain 3. a full scale study (n=20+20) addressing the efficacy and feasibility of iet in the prevention of chronicity of sub-acute low back pain

to assess the efficacy of iet on the chronification of lbp, participants who are found to have a higher risk of pain chronification due to the presence of a biomarker (positive mpfc-nac connectivity) will be randomized to the intervention group (iet) or control group a (treatment as usual). to assess how well this biomarker predicts the chronification of lbp, participants who are not found to have the biomarker will be assigned to control group b (treatment as usual).

Eligibility criteria:
inclusion criteria: the selection of subjects will meet same criteria as in the study by baliki et al. (2010). * low back pain diagnosed by a clinician * low back pain intensity \> 40/100 on nrs * low back pain duration 4-12 weeks exclusion criteria: * other chronic painful condition * systemic disease * history of head injury * diagnosed psychiatric disorders * depression exceeding mild depression (score \> 19), as defined by beck's depression inventory (bdi)

Keywords: prevention sub-acute low back pain interoceptive
glp-1: acute effects on kidney function in healthy men

Conditions: Kidney Functional

Summary: the purpose of this study is to investigate how glucagon-like peptide 1 (glp-1) affects kidney function in healthy young men. the hypothesis is that glp-1 induces a positive effect on kidney hemodynamics.


Eligibility criteria:
inclusion criteria: * healthy young men exclusion criteria: * any chronic diseases
seasonal influenza vaccine high dose boosting in solid organ transplant recipients

Conditions: Solid Organ Transplant

Summary: in solid organ transplant (sot) the receipt of influenza vaccine in an influenza season is associated with decreased disease severity as demonstrated by the presence of pneumonia and icu admissions. different strategies have been assessed to optimize vaccine efficacy and immunogenicity of the influenza vaccine in the solid organ transplant recipient (sotr). the primary objective of the study is to evaluate the immunogenicity of 2 doses of the high dose influenza vaccine utilizing neutralizing antibody assays. a control group receiving 1 hd influenza vaccine will be included.


Eligibility criteria:
inclusion criteria: * \>=18 years old who underwent a solid organ transplant (liver, lung, heart, kidney, pancreas) \> 1 year prior to enrollment * at least 1-year post-transplant * able and willing to provide informed consent * able and willing to undergo all study activities throughout the duration of the study exclusion criteria: * confirmed pregnancy * receipt of atg or carfilzomib within the past 3 months * receipt of rituximab within the past 3 months * receipt of basiliximab within the past 3 months * prednisone dose \>= 20 mg/day at the time of enrollment * history of a severe allergy to influenza vaccine (i.e. guillain barre syndrome, anaphylaxis or angioedema)
a real-world evidence study to evaluate oral health related quality of life using an anti-sensitivity toothpaste

Conditions: Dentin Sensitivity

Summary: the purpose of this study is to evaluate changes in oral health-related quality of life (ohrqol) in participants suffering from dentinal hypersensitivity (dh) symptoms following the use of anti-sensitivity toothpaste for 24 weeks.

this study will be a virtual, prospective, twenty-four weeks, open label study in participants with dh (self-reported symptoms). participants self-perception of dh will be evaluated by completion of a validated ohrqol questionnaire (dentin hypersensitivity experience questionnaire-48 \[dheq-48\]) at baseline, 4, 8, 12, 16, 20 and 24 weeks.

Eligibility criteria:
inclusion criteria: * provision of consent indicating that the participant has been informed of all pertinent aspects of the study. * the participant must be able to complete all activities as shown in the schedule of activities independently on their smart devices. * participant who has tooth sensitivity (self-reported symptoms). exclusion criteria: * a participant whose sensitivity could be caused by other factors or clinical pathology as established by the screening questionnaire, which also includes: * a participant who has been/is on multiple prescription medications to treat severe acid reflux on regular basis or considered surgery for acid reflux * a participant with full or partial denture * a participant who has undergone treatment within 6 months of screening or is currently under treatment for periodontal or gum disease * a participant with active periodontitis * a participant with active caries * a participant with any chronic and/or severe painful health conditions which lead to regular use pain medications (more than 3 days a week) * a participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients: potassium nitrate (5 percent \[%\]), sodium fluoride (0.15% weight/volume \[w/v\] fluoride ion), water, sorbitol, hydrated silica, glycerin, cocamidopropyl betaine, flavor, xanthan gum, titanium dioxide, sodium saccharin, sodium hydroxide, sucralose, yellow 10, blue 1.
efficacy of gamma camera used intraoperatively for id of sentinel lymph nodes w/ lymphoscintigraphy

Conditions: Multiple Myeloma; Breast Cancer

Summary: this study evaluates the ability of a prototype intraoperative handheld gamma camera (pihgc) to image (detect) sentinel lymph nodes (slns) in melanoma and breast cancer during surgical excision, as compared to standard of care intraoperative gamma probes (gp). the unit of study in this trial was snls rather individual participants. each device was assessed for relative node detection sensitivity (s) of those slns.

lymphoscintigraphy is an accepted and commonly-performed procedure used for staging of certain cancers, especially melanoma and breast cancer. it involves injecting a small amount of radioactivity under the skin in order to identify lymph nodes which should be biopsied (ie, the "sentinel lymph node, sln") to determine if cancer has spread. the study objective was to evaluate the potential benefit of a new, camera-based technology (prototype device) which allows actual images to be obtained intra-operatively in the identification of sentinel nodes. each device was assessed for relative node detection sensitivity (s), defined as the proportion of sentinel lymph nodes (slns) that were identified with each instrument, with the proportion determined as the number of true positives (tp) divided by the total evaluated (n).

Eligibility criteria:
inclusion criteria * malignancy for which sentinel node biopsy with lymphoscintigraphy are indicated as part of the standard of care for tumor staging * age 18 or greater. * healthy enough for surgery * able to understand and willing to sign a written informed consent document. exclusion criteria * no exclusion requirements due to co-morbid disease or intercurrent illness. * documented allergy to colloid. * lymphoscintigraphy presents excessive high risk, eg, a consideration if pregnant or lactating
study of bavituximab plus docetaxel in patients with locally advanced or metastatic non-squamous non small-cell lung cancer

Conditions: Non-small-cell Lung Cancer

Summary: the primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.


Eligibility criteria:
inclusion criteria: * adults over age 18 years of age with a life expectancy of at least 3 months. * histologically or cytologically confirmed stage iiib or stage iv non squamous non-small-cell lung cancer (nsclc) who have progressed after 1 chemotherapy regimen. * measurable disease by response evaluation criteria in solid tumors (recist, version 1.1) on cross-sectional imaging that is at least 2 cm in longest diameter. * eastern cooperative oncology group (ecog) performance status ≤ 2. * adequate hematologic, renal, and hepatic function. * pt/inr ≤ 1.5 × uln; aptt time ≤ 1.5 × uln. * new york heart association classification i or ii exclusion criteria: * squamous, small cell, or mixed histology. * known history of bleeding diathesis or coagulopathy. * cavitary tumors or tumors invading or abutting large blood vessels. * bleeding: clinically significant bleeding such as gross hematuria, gi bleeding and hemoptysis within 12 months of screening. * venous thromboembolic events within 6 months of screening. * ongoing therapy with oral or parenteral anticoagulants. * concurrent estrogens, anti-estrogens or progesterone compounds. * radiotherapy within 2 weeks or major surgery within 4 weeks preceding study day 1. * symptomatic or clinically active brain metastases. * symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction or unstable angina pectoris within 6 months of screening. * grade 2 or higher peripheral neuropathy

Keywords: nsclc second-line lung cancer non small cell lung cancer bavituximab monoclonal antibody
a study of clsp-1025 in adult patients with solid tumors that harbor the p53 r175h mutation

Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Colorectal Adenocarcinoma; Pancreatic Adenocarcinoma; Lung Cancer; Ovarian Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Bladder Cancer

Summary: phase 1 dose escalation and expansion study of clsp-1025, a first-in-class hla-a\*02:01 specific t cell engager (tce) targeting solid tumors that harbor the p53 r175h mutation.

this phase 1, open-label, multicenter study is designed to evaluate the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and preliminary clinical activity of clsp-1025 when administered to hla-a\*02:01-positive adult patients with advanced solid tumors that harbor the p53 r175h mutation. the study will be conducted in 2 parts: part a monotherapy dose escalation to determine the recommended dose(s) for expansion (rde\[s\]) and part b monotherapy expansion to explore the preliminary antitumor activity as well as further characterize the safety, tolerability, pk, and pd of clsp-1025 at the rde(s).

Eligibility criteria:
key inclusion criteria: * patients must be at least 18 years of age at the time of signing the informed consent. * patients must be willing and able to provide written informed consent * patients must have locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists * tumors must harbor a tp53 r175h variant mutation confirmed by an accredited laboratory-based test * patients must be hla-a\*02:01 positive by central assay * eastern cooperative oncology group (ecog) performance status of 0 to 1 at the time of enrollment * adequate hematological, renal and hepatic function * per investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation key exclusion criteria: * patients with li-fraumeni syndrome or other known germline p53 r175h mutation * patients who have received other p53 r175h-directed therapies * patients who have not fully recovered from adverse events due to previous anticancer therapies * patients with active infection requiring systemic antimicrobial therapy * any other primary malignancy within the 2 years prior to enrollment (except for non- melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or prostate cancer in remission. * known active central nervous system metastases and/or carcinomatous meningitis

Keywords: clsp-1025 t cell engager tce tp53
internal iliac artery occlusion in placenta accreta

Conditions: Placenta Accreta

Summary: this is a randomized study to assess the efficacy of prophylactic bilateral internal iliac artery occlusion performed prior to planned surgical management for placenta accreta spectrum (pas). the intervention group would receive balloon occlusion, ureteric stenting and caesaeran hysterectomy while the control group would undergo the same procedure, excluding balloon occlusion. the primary outcome is to demonstrate a three pint or greater reduction in pack cell transfusion requirement.

interventional radiology, including internal iliac artery occlusion, has been used as an adjunct in the management of placenta accreta spectrum (pas). retrospective studies have shown benefit in terms of reduction of blood loss. however, studies reported in literature vary widely in terms of the exact surgical procedure undertaken, in conjunction with the radiological intervention. the radiological intervention itself lacks standardization, occurring at different anatomical levels, ranging from infrarenal aortic occlusion to internal iliac or uterine artery. furthermore, there have been reported cases of arterial thrombosis associated with arterial occlusion. we sought to clarify the effectiveness of a standardized approach , where perioperative bilateral internal iliac artery occlusion is performed followed by bilateral ureteric stenting and caesarean hysterectomy. the control group would undergo the exact procedure, excluding internal iliac artery occlusion. patients would be randomized but neither the patient nor surgeon could be blinded. the primary outcome would be to demonstrate a three pint or greater reduction in packed cell transfusion. secondary outcomes include a difference in estimated blood loss, additional blood product transfusion, unplanned additional surgical procedure, serious complications arising from internal iliac artery occlusion, total procedural time and early neonatal outcome.

Eligibility criteria:
inclusion criteria: * all pregnant women with prenatally diagnosed placenta accreta spectrum exclusion criteria: * women who declined to participate * women with bleeding diathesis or severe thrombocytopenia \<100k x 1,000,000/l * surgery performed prior to 28 weeks of gestation

Keywords: balloon occlusion iliac artery interventional radiology postpartum hemorrhage blood transfusion
non-contrast enhanced cardiac magnetic resonance imaging in the diagnosis and classification of pulmonary hypertension

Conditions: Pulmonary Hypertension; Elevated Mean Pulmonary Arterial Pressure; Normal Mean Pulmonary Arterial Pressure

Summary: pulmonary hypertension (ph) is a life-threatening cardiovascular disease characterized by pathological elevation of mean pulmonary arterial pressure (mpap) \>/= 25 mmhg at rest. mpap \< 20 mmhg is defined as normal, values in the range between 21-24 mmhg are described as "borderline ph" diagnosed by right heart catheterization. based on the etiology, ph is assigned to 5 groups (who, data point, 2008), whereas classification of disease is an important prognostic and therapy-deciding criterion. cardiac magnetic resonance tomography (cmr) provides a reliable technique to estimate elevated mean pulmonary arterial pressure from period of existence of a vortical motion of blood flow in the main pulmonary artery. vortex can be visualized in 3-dimensional vector field, particle trace and streamline representations and can be analysed with respect to vortex related measures (geometry of center, vortex formation, vorticity, propagation dynamics ...). furthermore t1-mapping and non-contrast enhanced lung perfusion/ventilation scans represent promising techniques for ph characterization. aim of this explorative study is to 1. analyse ph-associated blood flow characteristics in the heart and the surrounding great vessels with respect to the 5 groups of ph, and 2. investigate the hemodynamic state of "borderline ph" compared to normal mpap and manifest ph by non-contrast cmr.


Eligibility criteria:
inclusion criteria: * patients with suspected or known ph scheduled for routine right-heart catheterization, * ability to give informed consent. exclusion criteria: * general mr exclusion criteria eg. patients with metal devices or other magnetic material in or on the subjects body which will be hazardous for mr investigation (e.g. heart pace-maker, brain aneurysm clip, nerve stimulators, electrodes, penile implants, coloured contact lenses, patch to deliver medications through the skin, any metal implants as rods, joints, plates, pins, screws, nails or clips, embolization coil, or any metal fragments or shrapnel in the body), * patients with tendency toward claustrophobia, * hemodynamically unstable patients, * pregnancy.
analgesic efficacy and safety of adl5859 in subjects with acute dental pain after third molar extraction

Conditions: Acute Pain

Summary: the objective of this study is to evaluate the analgesic efficacy and safety of adl5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.


Eligibility criteria:
key inclusion criteria: * have 2 or more 3rd molars requiring extraction, including at least 1 partially or completely bone-impacted mandibular molar * experience moderate to severe pain intensity as measured by the numeric pain rating scale (nprs) (score ≥ 5) within 6 hours after surgery * for male subjects, be surgically sterile or agree to use an appropriate method of contraception or have a sexual partner who is surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive * for female subjects, be using contraceptives, be postmenopausal, or have undergone hysterectomy or tubal ligation * be able to take oral study medications key exclusion criteria: * have positive results either on the urine screening tests for opiates, tetrahydrocannabinol,cocaine, amphetamines, barbiturates, benzodiazepines, phencyclidine, or propoxyphene or on the alcohol breathalyzer test * have a history of alcoholism or drug addiction or abuse within 5 years before dosing with study medication * have a history of chronic use (defined as daily use for \> 2 weeks) of glucocorticoids,nonsteroidal anti-inflammatory drugs, or opiates for any condition within 6 months of study medication administration * have a known allergy or history of significant reaction to any of the known treatment medications (adl5859-like compounds or ibuprofen) or rescue pain medication (acetaminophen) * have significant renal or hepatic disease, as indicated by clinical laboratory assessment * have a known history of epilepsy or seizure disorder, including history of febrile seizure, or any other medical or psychiatric condition that, in the judgment of the investigator, would put the subject at risk while in the study, could influence the results of the study, or could negatively affect the subject's ability to participate in the study * have a history or evidence of orthostatic hypotension at screening have a history of significant head trauma (head injury with loss of consciousness)

Keywords: delta opioid agonist dental pain